| Literature DB >> 32864932 |
Doğuş Hemşinli1, Saban Ergene1, Sedat Ozan Karakişi1, Tolga Mercantepe2, Levent Tumkaya2, Adnan Yilmaz3, Kerimali Akyilzdiz4.
Abstract
INTRODUCTION: Ischemia-associated mortality caused by aortic cross-clamps, as in ruptured abdominal aorta aneurysm surgeries, and reperfusion following their removal represent some of the main emergency conditions in cardiovascular surgery. The purpose of our study was to examine the potential protective effect of tea grape against aortic occlusion-induced lung injury using biochemical, histopathological, immunohistochemical, and quantitative analyses.Entities:
Keywords: Alveolar Epithelial Cells; Aorta, Abdominal; Apoptosis; Edema; Glutathione, Glycerol; Lung; Lung Injury; Oxidative Stress; Rats; Reperfusion, Ischemia
Mesh:
Substances:
Year: 2020 PMID: 32864932 PMCID: PMC7454615 DOI: 10.21470/1678-9741-2019-0392
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Modified (from Matute-Bello et al.[19]) Alveolar and Lung Histopathological Damage Score (ALHDS).
| Findings | Score | ||
|---|---|---|---|
| 0 | 1 | 2 | |
| Edema in interstitial areas | None (< 5%) | Mild (6-50%) | Severe > 50% |
| Vascular congestion | None (< 5%) | Mild (6-50%) | Severe > 50% |
| Alveolar septum thickness (treatment group/control group) | ≤ x1 | x1-x2 | ≥ x2 |
| Inflammation | None (< 5%) | Mild (6-50%) | Severe > 50% |
Fig. 1Graphs comparing the median and interquartile range of MDA and GSH between the groups.
Fig. 2Representative light microscopic images of H&E-stained lung tissue sections. Type I pneumocytes (arrow), Type II pneumocytes (arrowhead).
A(x20)-B(x40): Normal lung tissue histology in control group sections. [ALHDS score median: 1 (1-1.5)]. C(x20)-D(x40): Sections from the I/R group show diffuse edematous areas (asterisk) in interalveolar regions and vascular congestion (c). [ALHDS score median: 6.5 (5-7.5)]. E(x20)-F(x40): Sections from the I/R+Glycerol group exhibit thickening of the alveolar septal wall and edema interalveolar area (asterisk). Vascular congestion (c) can also be seen [ALHDS score: 6 (5-6.5)]. G(x20)-H(x40): Sections from the TG group exhibit decreased thickening [ALHDS score: 3 (2-3)] of the alveolar septal wall and edema.
Fig. 3Comparison of the semi-quantitative analysis results between the groups. Median ± 25%-75% interquartile range. aP=0.00; compared with the control group. bP=0.05; compared with the ischemia/reperfusion (I/R) group. cP=0.021; compared with the glycerol (Gly) + I/R group. dP=0.003; compared with the control group. eP=0.006; compared with the control group. fP=0.003; compared with the I/R group. gP=0.006; compared with the Gly + I/R group. hP=0.002; compared with the I/R group. iP=0.013; compared with the I/R group. jP=0.0013; compared with the Gly + I/R group. kP=0.01; compared with the I/R group. lP=0.00; compared with the Gly + I/R group. Kruskal-Wallis - Tamhane’s T2 test. TG=tea grape
Alveolar septum thickness analysis results.
| Group | Alveolar wall thickness (µm) (median and interquartile range) | Alveolar septum thickness (treatment group/control group) | Matute-Bello et al.[ |
|---|---|---|---|
| Control | 9.62 (7.56-10.10) | 1.00 | 0 (<x2) |
| I/R | 19.45 (18.04-21.82) | 2.02 | 2 (≥ x2) |
| Glycerol + I/R | 19.35 (18.63-22.58) | 2.01 | 2 (> x2) |
| I/R + tea grape | 10.10 (7.81-11.25) | 1.05 | 1 (x1-x2) |
P=0.000; compared with the control group.
P=0.000; compared with the ischemia/reperfusion (I/R) group.
P=0.000; compared with the glycerol + I/R group.
P=0.989; compared with the glycerol + I/R group.
Kruskal-Wallis - Tamhane's T2 test.
Fig. 4Comparison of the median alveolar septum thickness between the groups.
Fig. 5Representative light microscopic images of caspase-3 antibody-stained lung tissue sections.
A: Sections from the control group exhibit normal Type I (blue arrowhead) and Type II pneumocytes (blue arrow) [median caspase-3 positivity score: 0.00 (0-1)]. x40. B: Sections from the I/R group showing intense caspase-3 positivity in Type I (black arrowhead) and Type II pneumocytes (black arrow) [median caspase-3 positivity score: 2.00 (2-2.5)]. x40. C: Glycerol+I/R group sections showing intense apoptosis in Type I (black arrowhead) and Type II pneumocytes (black arrow) [median caspase-3 positivity score: 2.00 (2-2)]. x40. D: Sections from the TG treatment group showing decrease caspase-3 positivity in Type I (blue arrowhead) and Type II pneumocytes (blue arrow) [median caspase-3 positivity score: 1.00 (0-1)]. x40.
Fig. 6Distribution of the median grade scores of caspase-3 positivity between groups. Gly=glycerol; I/R=ischemia/reperfusion; TG=tea grape
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| ALHDS | = Alveolar and Lung Histopathological Damage Score | IU | = International units | |
| Gly | = Glycerol | LPO | = Lipid peroxidation | |
| GSH | = Glutathione | MAP | = Mean arterial pressure | |
| HCl | = Hydrochloride | MDA | = Malondialdehyde | |
| i.p | = Intraperitoneal | RAAA | = Ruptured abdominal aorta aneurysm | |
| I/R | = Ischemia/reperfusion | ROS | = Reactive oxygen species | |
| IHC | = Immunohistochemical | TG | = Tea grape | |
| Authors' roles & responsibilities | |
|---|---|
| DH | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| SE | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| SOK | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| TM | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| LT | Substantial contributions to the conception or design of the work; or the analysis, or interpretation of data for the work; final approval of the version to be published |
| AY | Substantial contributions to the conception or design of the work; or the analysis, or interpretation of data for the work; final approval of the version to be published |
| KA | Substantial contributions to the conception or design of the work; or the analysis, or interpretation of data for the work; final approval of the version to be published |